Welcome to the US Oncology Medical Information Website
The information provided on this website was created by Takeda Oncology Medical Affairs teams for healthcare professionals in the US. It is designed to provide self-service access to medical information and medical affairs content about Takeda Oncology products, pipeline and disease education. This website may include information that has not been approved by the US Food and Drug Administration and it is not intended as medical advice. By searching across this website you confirm the unsolicited nature of the inquiry.
Please confirm that you agree and that you are a Health Care Professional registered to practice in the US?
News & Announcements
Fruquintinib – Takeda To Acquire License
With Marketing Authorization Submissions in the U.S., European Union and Japan Planned in 2023, Fruquintinib Offers a Potential
Phase 3 Trial of ICLUSIG® (ponatinib)
The PhALLCON Study Is the First Global, Phase 3, Registrational, and Only Head-To-Head Clinical Trial Comparing
Takeda to Acquire Adaptate Biotherapeutics
Acquisition Adds Adaptate’s Novel Antibody-based γδ T-cell Engager Platform to Takeda’s Immuno-oncology Portfolio
Takeda to Acquire GammaDelta Therapeutics
Acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms